Hans Schambye

2.1k total citations
35 papers, 1.5k citations indexed

About

Hans Schambye is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Hans Schambye has authored 35 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Immunology and 7 papers in Oncology. Recurrent topics in Hans Schambye's work include Galectins and Cancer Biology (15 papers), Receptor Mechanisms and Signaling (9 papers) and Peptidase Inhibition and Analysis (6 papers). Hans Schambye is often cited by papers focused on Galectins and Cancer Biology (15 papers), Receptor Mechanisms and Signaling (9 papers) and Peptidase Inhibition and Analysis (6 papers). Hans Schambye collaborates with scholars based in Denmark, Sweden and United Kingdom. Hans Schambye's co-authors include Siv A. Hjorth, Thue W. Schwartz, William J. Greenlee, Ulrik Gether, Hakon Leffler, Ulf J. Nilsson, Alison C. MacKinnon, Derk J. Bergsma, Ganesh M. Sathe and Ralph A. Rivero and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Gastroenterology.

In The Last Decade

Hans Schambye

35 papers receiving 1.5k citations

Peers

Hans Schambye
Matt Elliott United States
Sandra Braun Germany
Briggs Morrison United States
Ágnes Balogh Hungary
Vanessa Núñez United States
Paramita Ray United States
Andrew Booth United Kingdom
David Austin United Kingdom
Li Zhu China
Jane Yu United States
Matt Elliott United States
Hans Schambye
Citations per year, relative to Hans Schambye Hans Schambye (= 1×) peers Matt Elliott

Countries citing papers authored by Hans Schambye

Since Specialization
Citations

This map shows the geographic impact of Hans Schambye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Schambye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Schambye more than expected).

Fields of papers citing papers by Hans Schambye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Schambye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Schambye. The network helps show where Hans Schambye may publish in the future.

Co-authorship network of co-authors of Hans Schambye

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Schambye. A scholar is included among the top collaborators of Hans Schambye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Schambye. Hans Schambye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
MacKinnon, Alison C., Duncan C. Humphries, James A. Roper, et al.. (2024). Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver. European Journal of Pharmacology. 985. 177077–177077. 4 indexed citations
2.
Aslanis, Vassilios, Robert J. Slack, Lise Gravelle, et al.. (2024). Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer Chemotherapy and Pharmacology. 94(5). 707–720. 1 indexed citations
3.
Aslanis, Vassilios, Michael A. Gray, Robert J. Slack, et al.. (2024). Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment. Clinical Drug Investigation. 44(10). 773–787. 4 indexed citations
4.
Aslanis, Vassilios, Robert J. Slack, Alison C. MacKinnon, et al.. (2023). Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer Chemotherapy and Pharmacology. 91(3). 267–280. 25 indexed citations
5.
Humphries, Duncan C., Ross Mills, Brian J. McHugh, et al.. (2022). Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation. Frontiers in Pharmacology. 13. 949264–949264. 22 indexed citations
6.
7.
Vuong, Lynda, Claire Rooney, Brian J. McHugh, et al.. (2019). An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade. Cancer Research. 79(7). 1480–1492. 104 indexed citations
8.
Stegmayr, John, Fredrik R. Zetterberg, Michael C. Carlsson, et al.. (2019). Extracellular and intracellular small-molecule galectin-3 inhibitors. Scientific Reports. 9(1). 2186–2186. 73 indexed citations
9.
Delaine, Tamara, P.M. Collins, Alison C. MacKinnon, et al.. (2016). Galectin‐3‐Binding Glycomimetics that Strongly Reduce Bleomycin‐Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition. ChemBioChem. 17(18). 1759–1770. 151 indexed citations
10.
Nykjær, Anders, et al.. (2009). Assessing low-dose gentamicin-induced kidney injury in rats by analysis of urine. Journal of Pharmacological and Toxicological Methods. 60(3). 316–320. 4 indexed citations
11.
Hellström, Per M., J Hein, Peter Bytzer, et al.. (2008). Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind study. Alimentary Pharmacology & Therapeutics. 29(2). 198–206. 72 indexed citations
12.
Christiansen, Jesper Riis, et al.. (2003). Glycosylation of an N-Terminal Extension Prolongs the Half-Life and Increases the in Vivo Activity of Follicle Stimulating Hormone. The Journal of Clinical Endocrinology & Metabolism. 88(7). 3227–3235. 94 indexed citations
13.
Ghanouni, Pejman, Hans Schambye, Roland Seifert, et al.. (2000). The Effect of pH on β2 Adrenoceptor Function. Journal of Biological Chemistry. 275(5). 3121–3127. 99 indexed citations
14.
Schambye, Hans. (1996). Effect of Different Buffers on the Biocompatibility of Capd Solutions. Peritoneal Dialysis International. 16(1_suppl). 130–136. 26 indexed citations
15.
Schambye, Hans, et al.. (1995). Non-peptide Angiotensin Agonist. Journal of Biological Chemistry. 270(4). 1493–1496. 84 indexed citations
16.
Schambye, Hans, Siv A. Hjorth, Joseph Weinstock, & Thue W. Schwartz. (1995). Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor.. Molecular Pharmacology. 47(3). 425–431. 29 indexed citations
17.
Hjorth, Siv A., Hans Schambye, William J. Greenlee, & Thue W. Schwartz. (1994). Identification of peptide binding residues in the extracellular domains of the AT1 receptor.. Journal of Biological Chemistry. 269(49). 30953–30959. 150 indexed citations
18.
Schambye, Hans, Siv A. Hjorth, Wolfgang Wienen, et al.. (1994). Mutations in transmembrane segment VIJ of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists. British Journal of Pharmacology. 113(2). 331–333. 22 indexed citations
19.
Schambye, Hans, et al.. (1993). The Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis Solutions with Different Bicarbonate/Lactate Ratios. Peritoneal Dialysis International. 13(2_suppl). 116–118. 27 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matt Elliott Breakdown of academic impact, for papers by Sandra Braun Breakdown of academic impact, for papers by Briggs Morrison Breakdown of academic impact, for papers by Ágnes Balogh Breakdown of academic impact, for papers by Vanessa Núñez Breakdown of academic impact, for papers by Paramita Ray Breakdown of academic impact, for papers by Andrew Booth Breakdown of academic impact, for papers by David Austin Breakdown of academic impact, for papers by Li Zhu Breakdown of academic impact, for papers by Jane Yu
Rankless by CCL
2026